We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Expanded Indication

News List

FOQUEST Receives Approval for Expanded Indication for Children and Adolescents with ADHD firstwordpharma
March 13, 2019
Today's news is an exciting development for young Canadians and their families who now have a new option to help manage their ADHD," said Purdue Pharma (Canada) President and CEO David Pidduck.
FDA Approves Expanded Indication for Truvada (emtricitabine and tenofovir disoproxil fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents drugs
May 17, 2018
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)